Filing Flows › Coherus Oncology (CHRS) › Q3 2025
Coherus Oncology (CHRS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Coherus Oncology (CHRS) reported revenue of $11.6M for the third quarter 2025 (Q3 2025), +91% from a year earlier and +13% from the quarter before. Operating margin was -383.1%, net loss $35.5M (307.1% of revenue).
Coherus Oncology, Q3 2025: revenue $11.6M (+91% year over year), operating margin -383.1%, net loss $35.5M, operating cash flow −$46.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.6M | +13% | +91% |
| Operating profit | −$44.3M | — | — |
| Net earnings | −$35.5M | -112% | — |
| Operating cash flow | −$46.3M | — | — |
What changed
Revenue was $11.6M in Q3 2025, up 91% year over year and up 13% from the previous quarter. Toripalimab was the largest line at 97% of revenue. Toripalimab added $5.3M year over year (up 92%), 97% of the total change.
Operating costs exceeded revenue by $44.3M, an operating margin of -383.1%. Total costs grew 6% against revenue growth of 91%. The fastest-growing cost line was Cost of revenue (+36%). The quarter ended with a net loss of $35.5M, after a profit of $297.8M the previous quarter.
Operating cash flow was −$46.3M. Non-cash charges added back $300K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $14.5M.
Questions
What was Coherus Oncology's revenue in the third quarter 2025?
Coherus Oncology (CHRS) reported revenue of $11.6M for the third quarter 2025 (Q3 2025), +91% from a year earlier and +13% from the quarter before.
Was Coherus Oncology profitable in the third quarter 2025?
Operating loss was $44.3M (-383.1% of revenue) and net loss $35.5M.
Source: Coherus Oncology 10-Q on SEC EDGAR.